Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Metastatic Pancreatic Cancer
Related studies linked through entity extraction aliases.
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
- Status
- RECRUITING
- Phase
- PHASE1
Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
- Status
- COMPLETED
- Phase
- N/A
Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
- Status
- UNKNOWN
- Phase
- N/A
Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen
- Status
- UNKNOWN
- Phase
- PHASE2
Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity
- Status
- COMPLETED
- Phase
- N/A
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
- Status
- TERMINATED
- Phase
- PHASE2
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
- Status
- TERMINATED
- Phase
- PHASE2
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI
- Status
- COMPLETED
- Phase
- PHASE2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2